92 related articles for article (PubMed ID: 24393150)
1. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood.
Rae C; Furlong W; Jankovic M; Moghrabi A; Naqvi A; Sala A; Samson Y; DePauw S; Feeny D; Barr R
Eur J Cancer Care (Engl); 2014 Nov; 23(6):779-85. PubMed ID: 24393150
[TBL] [Abstract][Full Text] [Related]
2. Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
Gupta S; Sutradhar R; Li Q; Athale U; Bassal M; Breakey V; Gibson PJ; Patel S; Silva M; Zabih V; Pechlivanoglou P; Pole JD; Mittmann N
Eur J Cancer; 2021 Jul; 151():126-135. PubMed ID: 33979728
[TBL] [Abstract][Full Text] [Related]
3. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols.
Niemeyer CM; Reiter A; Riehm H; Donnelly M; Gelber RD; Sallan SE
Ann Oncol; 1991; 2(10):745-9. PubMed ID: 1801880
[TBL] [Abstract][Full Text] [Related]
4. Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol.
Rae C; Furlong W; Feeny D; Couchman R; Silverman L; Sallan S; Laverdiere C; Clavell L; Michon B; Kelly K; Larsen E; Pullenayegum E; Athale U; Barr R
J Pediatr Hematol Oncol; 2018 Nov; 40(8):580-587. PubMed ID: 29901560
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
Badowska W
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
[TBL] [Abstract][Full Text] [Related]
7. Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91.
von Stackelberg A; Karatchunsky A; Kudrjashova J; Miakova N; Belikova L; Rumiantzev A; Hartmann R; Henze G
Eur J Cancer; 1999 Sep; 35(9):1349-55. PubMed ID: 10658526
[TBL] [Abstract][Full Text] [Related]
8. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Lejhancova-Tousovska K; Zapletal O; Vytiskova S; Strbackova P; Sterba J
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):144-54. PubMed ID: 22227959
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome for children with non-high risk acute lymphoblastic leukaemia after using an ALL IC-BFM 2002-based protocol in Shanghai, China.
Gao YJ; Qian XW; Lu FJ; Zhai XW; Wang HS; Li J
Br J Haematol; 2013 Feb; 160(3):363-7. PubMed ID: 23151178
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
11. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
Attarbaschi A; Pisecker M; Inthal A; Mann G; Janousek D; Dworzak M; Pötschger U; Ullmann R; Schrappe M; Gadner H; Haas OA; Panzer-Grümayer R; Strehl S;
Br J Haematol; 2010 Jan; 148(2):293-300. PubMed ID: 19821827
[TBL] [Abstract][Full Text] [Related]
13. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia.
Pickard AS; Topfer LA; Feeny DH
J Natl Cancer Inst Monogr; 2004; (33):102-25. PubMed ID: 15504922
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Pichler H; Möricke A; Mann G; Teigler-Schlegel A; Niggli F; Nebral K; König M; Inthal A; Krehan D; Dworzak MN; Janousek D; Harbott J; Schrappe M; Gadner H; Strehl S; Haas OA; Panzer-Grümayer R; Attarbaschi A;
Br J Haematol; 2010 Apr; 149(1):93-100. PubMed ID: 20067563
[TBL] [Abstract][Full Text] [Related]
15. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
16. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
17. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
[TBL] [Abstract][Full Text] [Related]
19. Treatment of childhood acute lymphoblastic leukaemia with the BFM regimen.
Kudva GC; Chandy M; Raghupathy P; Dennison D; Srivastava A; Bhushan V; Singh R
Indian J Cancer; 1994 Jun; 31(2):78-85. PubMed ID: 7927453
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology.
van Litsenburg RR; Uyl-de Groot CA; Raat H; Kaspers GJ; Gemke RJ
Pediatr Blood Cancer; 2011 Dec; 57(6):1005-10. PubMed ID: 21618420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
